Publications

Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 2004;5(3):465-81. http://www.ncbi.nlm.nih.gov/pubmed/15208206?ordinalpos=58&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Cole BF, Gelber RD, Gelber S, Mukhopadhyay P. A quality-adjusted survival model (Q-TWiST) for advanced stage cancer. J Biopharmaceutical Stat 2004;14:111-124. http://www.ncbi.nlm.nih.gov/pubmed/15027503?ordinalpos=63&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, …. Gelber RD, for the HERA Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16):1659-1672. http://www.ncbi.nlm.nih.gov/pubmed/16236737?ordinalpos=43&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Breast International Group (BIG) 1-98 Collaborative Group (Keshaviah A, Gelber RD, Price KN). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353 (26):2747-2757. http://www.ncbi.nlm.nih.gov/pubmed/16382061?ordinalpos=41&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn H-J, and Panel Members. Progress and promise: highlights of the International expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133-1144. http://www.ncbi.nlm.nih.gov/pubmed/17675394?ordinalpos=21&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum